Amlitelimab, an OX40 ligand–targeting therapy that modulates T-cell-mediated inflammation without causing cell depletion, ...
Sanofi's amlitelimab confirms its potential in atopic dermatitis In the SHORE phase 3 study, amlitelimab in combination with topical therapies met all primary and key secondary endpoints at Week ...
Sanofi's amlitelimab confirms its potential in atopic dermatitisIn the SHORE phase 3 study, amlitelimab in combination with topical therapies met ...
Alkermes (ALKS) shifts to fully integrated biopharma, leveraging Vibrance-2, Lybalvi growth, and Avadel buy to de-risk alixorexton. See more details here.
19d
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing
The market underappreciates TENX's late-stage pipeline and risk-adjusted asset value; we recommend buying ahead of Phase 3 data in H2 2026. Read the full analysis here.
MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License ...
Major stock indexes fell sharply Wednesday as investors digested the latest batch of bank earnings reports and readings on ...
The main objective of this randomized, double-blind, placebo-controlled study was to measure the impact of a multivitamin ...
Main outcome measures Cumulative time dependent intake of preservatives, including those in industrial food brands, assessed using repeated 24 hour dietary records and evaluated t ...
A new global dryland assessment using long-term satellite observations reveals widespread vegetation greening over the past ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results